Many patients are not responsive or tolerant to medical therapies for carotid atherosclerosis. Thus, elucidating the molecular mechanism for the pathogenesis and progression of carotid atherosclerosis and identifying new potential molecular targets for medical therapies that can slow progression of carotid atherosclerosis and prevent ischemic events are quite important.
Background
Atherosclerosis is an inflammatory disease that involves the accumulation of fibrous and/or fatty components in the intima of medium and large arteries such as the coronary artery, carotid artery, and peripheral artery, and the clinical manifestations vary with the arteries affected [1, 2] . Ischemic strokes and transient ischemic attacks may occur if the carotid artery is involved, and carotid atherosclerotic disease accounts for approximately 18-25% of all ischemic strokes [3] . Prevention of stroke in patients with carotid atherosclerosis depends on the degree of carotid stenosis. These preventive methods mainly include carotid endarterectomy, carotid stenting, and medical management such as with statins and antiplatelet agents [4, 5] . Although the medical management is effective and may even serve as an alternative to carotid endarterectomy in patients with asymptomatic carotid atherosclerosis, patients who are nonresponsive to medical therapies or not tolerant of the adverse effects may not benefit from present medical therapies [6] [7] [8] . Therefore, elucidating the molecular mechanism of the pathogenesis and progression of carotid atherosclerosis and identifying new potential molecular targets for medical therapies that can slow progression of carotid atherosclerosis and prevent ischemic events are quite important. The molecular mechanism mainly includes abnormal accumulation of lipids, immune response, and inflammation, and monocytes play an important role [1, 9] . Induced by chemokines, circulating monocytes can bind to adhesion molecules expressed by endothelial cells, migrating into the arterial wall and differentiating into macrophages. Previous studies focused on the role of circulating monocytes in the pathogenesis and progression of carotid atherosclerosis; however, few researchers have used weighted (gene) correlation network analysis (WGCNA) to construct gene co-expression networks for carotid atherosclerosis based on high-throughput data of peripheral blood mononuclear cells (PBMCs) in patients.
Zhang and Horvath first developed the WGCNA algorithm in 2005, which can be used for gene co-expression network construction, gene module detection, and hub gene identification, based on gene expression data [10] [11] [12] . Furthermore, gene modules and hub genes can be correlated with clinical traits if these data are available. The WGCNA R package was developed on the official R website (https://cran.r-project.org/), making it more convenient for researchers to conduct WGCNA. Although WGCNA was first developed for analyzing gene expression data, it can also be used for miRNA, lncRNA, and even metabolome [13] [14] [15] . Previous studies screened differentially expressed genes (DEGs) using microarray data of carotid atherosclerotic plaques. For instance, Razuvaev et al. identified 11 downregulated genes and 19 upregulated genes by comparing the gene expression profile between symptomatic and asymptomatic patients [16] . However, DEG screening cannot reveal the interaction among genes or identify genes with crucial biological functions.
In the present study, we focused on the possible underlying molecular mechanism of the occurrence of ischemic events. The mRNA microarray data of the Biobank of Karolinska Endarterectomies (BiKE) were included. The expression data of peripheral blood mononuclear cells for patients with ischemic events (the events group) and patients without ischemic events (the no-events group) during follow-up [17] were used in our analysis. The genes in the gene modules were subjected to functional enrichment analysis. Then, we mapped DEGs into the co-expression network of events group and obtained 1 DEG co-expression network. Furthermore, we identified crucial genes based on the DEG co-expression network. The potential diagnostic and prognostics values of the upregulated crucial genes were identified.
Material and Methods

Datasets
The dataset GSE21545, from the Biobank of Karolinska Endarterectomy (BiKE), was selected from the Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/). Series matrix file and platform data tables (GPL570) were downloaded.
DEG analysis
The series matrix file was annotated with GPL570 platform data tables, and the probe names in the matrix file were replaced by the gene symbols. Then, the 97 peripheral blood mononuclear cell (PBMC) samples were included in our analysis, in which 21 were samples of the events group and 76 were samples of the no-events group. Differentially expressed genes (DEGs) were screened using the "limma" R package. |log 2 (fold-change)|>2 and adjusted p<0.01 were set as the threshold of DEG screening.
Construction of co-expression network by WGCNA
Co-expression networks for both PBMC and plaque samples were constructed using the "WGCNA" R package. The algorithm filtered genes with the top 25% variance for further analysis, and WGCNA analysis was conducted for the events group (21 samples) and the no-events group (76 samples). The soft-power threshold b was chosen to ensure a scale-free topology. A topological overlap measure (TOM) matrix was created from the adjacency matrix to estimate the network's connectivity property. A clustering dendrogram was constructed using average linkage hierarchical clustering based on the e921692-2 TOM matrix. The threshold for modules size was set as 50 for both groups to generate modules with proper size, and similar modules were merged.
GO and KEGG pathway enrichment of gene modules
Gene ontology (GO) and Kyoto Encyclopedia of Genes Genomes (KEGG) pathway analyses were conducted for genes in modules we detected using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (https://david.ncifcrf.gov/) to determine the biological function and signaling pathway involved in these modules. Count number >2 and p<0.05 were set as thresholds for the analysis. The differences between co-expression networks for the events group and no-events group were compared based on the results of functional enrichment analysis.
Identification of hub genes and crucial genes
Hub genes were considered to be the gene which had the largest intramodular connectivity in each module. Then, we mapped the DEGs into a co-expression network in the events group using Cytoscape v3.7.0, and we obtained 1 DEG co-expression network. Isolated nodes and isolated nodes pairs were removed from the network. The Molecular Complex Detection (MCODE), a plugin in Cytoscape to detect core subnetworks, was used to identify crucial gene clusters based on the DEG co-expression network. Receiver operating characteristic (ROC) analysis and survival analysis were also conducted using the combination of the upregulated genes in the crucial gene cluster by SPSS 25.0 to show the potential diagnostic and prognostic value of upregulated crucial genes.
Results
Flowchart
The flowchart of our study is shown in Figure 1 . We constructed the co-expression networks for the events group and noevents group and detected gene modules. Then, DEG screening was conducted, and 183 DEGs were screened. The DEG co-expression network were constructed by mapping DEGs into the whole co-expression network of the events group. Based on the DEG co-expression network, crucial genes were identified, and their clinical significance was evaluated by ROC and survival analysis.
Screening of DEGs
With the threshold of |log 2 (fold-change)|>2 and p<0.01, 183 DEGs were screened with 122 upregulated and 61 downregulated genes. The heatmap and the volcano plot showed the expression pattern of DEGs ( Figure 2 ). Upregulated DEGs and downregulated DEGs with the top 10-fold-change are shown in Supplementary Table 1 .
Construction of the co-expression network for the events group and no-events group
One outlier (GSM892524) in the events group was removed, while all samples in the no-events group were included for further analysis, as shown in the sample clustering dendrogram ( Figure 3A and Supplementary Figure 1A ). The power of b=10 and 16 were chosen as the soft-threshold for the network of the events group and no-events group, respectively ( Figure 3B and Supplementary Figure 1B ). And the both the co-expression networks we constructed met the requirements of scalefree topology ( Figure 3C -3E and Supplementary Figure 1C -1E). We detected 8 gene modules for the events group and 6 gene modules for the no-events group ( Figure 3F and Supplementary Figure 1F ).
Comparison of co-expression patterns
KEGG pathway and GO-BP analysis were used to assess the biological function of genes for modules. Results of GO-BP and KEGG analyses are shown in Supplementary Tables 2 and 3 . The green-yellow module may be related to the occurrence of ischemic events. The green-yellow module is mainly associated 
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with inflammation and immune response. Nonetheless, pathways associated with inflammation and immune response were scattered in modules of the no-events group. The KEGG pathway GO-BP terms with the top 10 count numbers for greenyellow modules of the events group are shown in Figure 4 and Table 1 . These results indicate that PBMC might play a role in the occurrence of ischemic events through regulating inflammation and immune response.
Hub genes in modules of the events group and no-events group
Hub genes for modules of the events group and no-events group are shown in Table 2 . The hub genes of the green-yellow modules of the events group were killer cell immunoglobulin-like receptor, 2 Ig domains, and long cytoplasmic tail 5A (KIR2DL5A), which are killer cell immunoglobulin-like receptors (KIRs) and are mainly expressed by natural killer cells and subsets of T cells.
Identification of crucial genes mediating ischemic events
The DEG co-expression network was obtained by mapping DEGs into the whole co-expression network of the events group. The threshold for weighted edge was set as 0.1. After removing isolated nodes and isolated nodes pairs, a network with 16 nodes and 24 edges was generated ( Figure 5A ). MCODE detected 1 significant cluster consisting of 5 genes for the DEG co-expression network ( Figure 5B , Table 3 ). Among these 5 genes, 2 genes were upregulated (THRAP3 and RBM43) and 3 genes were downregulated (SIRT1, PEX1, and KLHDC2). Sirtuin 1 (SIRT1), a member of the sirtuin family, had the highest connectivity among the 5 crucial genes.
Combination of the 2 upregulated genes showed potential diagnostic and prognostic value ( Figure 6 ). 
DATABASE ANALYSIS
Discussion
We screened 183 DEGs, among which 122 were upregulated and 61 were downregulated (Figure 2 and Supplementary  Table 1 ). Weighted co-expression networks were constructed using the WGCNA algorithm. We detected 8 modules for the events group and 6 modules for the no-events group.
We also conducted KEGG pathway and GO-BP analysis ( Supplementary Tables 2 and 3 ) and found that pathways related to inflammation and immune response were mainly enriched in the green-yellow module of the events group. However, these pathways were dispersed in modules of the no-events group. Hub genes were considered to be genes which had the highest connectivity in each module (Table 2) . Then, the DEG co-expression network was obtained by mapping DEGs into the whole co-expression network of the events group, and crucial genes were identified by MCODE based on the DEG co-expression network. These crucial genes were THRAP3, RBM43, SIRT1, PEX1, and KLHDC2. SIRT1 had the highest connectivity among the 5 crucial genes, and the combination of 2 upregulated genes (THRAP3 and RBM43) showed potential prognostic and diagnostic value.
Perisic et al. used the same dataset and analyzed the expression signature of PBMCs, and the DEGs they screened were different from the DEGs in our study. They grouped patients into a symptomatic group and an asymptomatic group. In the symptomatic group, patients already had plaque instability, which was defined as transient ischemic attack (TIA), minor stroke (MF), and amaurosis fugax (AF) [18] . However, unlike the previous study, we classified patients into an events group and a no-events group, depending on the occurrence of ischemic events during follow-up [17] . The difference in grouping patients may account for the difference in DEG screening results.
Several previous studies conducted WGCNA on expression data of atherosclerosis. Using aortic samples from Apob tm2Sgy Ldlr tm1Her knockout mice, Deshpande et al. discovered that inflammation and immune response might play a role in the pathogenesis and progression of atherosclerosis, and identified several related genes (TM9SF1, LEPR, WIF1, and SP1) . In contrast to the sample Desphande et al. used, some researchers used human atherosclerotic samples from the GEO website and also found that inflammation and immune response might have important roles. Zhang et al. discovered crucial genes such as TNPO1 and ZDHHC17, while Wang et al. found that a lncRNA module was associated with inflammation and immune response. However, they did not elucidate the molecular mechanism based on the expression profiling of PBMC samples, and the grouping was also different [19] [20] [21] [22] .
The gene module detection and functional enrichment analysis indicated that the co-expression patterns in the events 
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group and no-events group were different. We found that inflammation and immune response were clustered in the greenyellow module of the events group. A previous study showed that CD14 + CD16monocyte has a proinflammatory phenotype, and increased circulating proinflammatory monocytes were observed in the atherosclerotic models of ApoE -/mice [23, 24] . Belge et al. also discovered that proinflammatory cytokines such as TNF-a can be produced by activated CD14 hi CD16 + monocytes, which might participate in atherosclerosis progression [25] . In addition, monocytes are involved in regulation of immune response in atherosclerosis. Some tissue macrophages and dendritic cells in the lesion originated from monocytes [26, 27] . Evans et al. found that T cell response can be regulated by monocytes [28] . Furthermore, the TLR-4 expression in CD14 hi CD16 + monocytes were correlated with occurrence of plaque progression and ischemic events in coronary artery disease [29] . In a recent experimental study, Bruen et al. showed that conjugated linoleic acid (CLA), which is an antiinflammatory lipid, can induce regression of atherosclerosis in ApoE -/mice. In mice fed CLA, more monocytes differentiated into anti-inflammatory M2 macrophages [30] . Sun et al. fed ApoE -/model mice phenytoin, a non-selective voltage-gated sodium channels antagonist, and the mice subsequently exhibited increased levels of anti-inflammatory monocytes and decreased levels of proinflammatory monocytes [31] . Statins were also found to affect monocytes in atherosclerosis. Using samples from patients, Gasbarrino et al. discovered that intensive statins therapy can downregulate the expression of the anti-inflammatory adiponectin-AdipoR pathway in monocytes and macrophages, instead of positively regulating this pathway, which may explain part of the residual cardiovascular risk in patients using statins [32] . These studies, together with our findings, suggest that monocytes participate in the pathogenesis and progression of atherosclerosis via mediating inflammation and immune response, both directly and indirectly.
The hub gene of the green-yellow module was KIR2DL5A, belonging to the KIR family, and it is mainly expressed by natural killer cells and T cells. KIR2DL5A is an inhibitory receptor of immune response [33] and it is involved in immune response to viral infection and prognosis of certain malignant diseases. Shan et al. reported that patients with KIR2DL5A -/2DL5B + genotype had increased HCV clearance [34] . In colorectal cancer, the presence of KIR2DL5A is related to increased complete response rate in patients treated with FOLFIRI chemotherapy [35] , and KIR2DL5A is also a protective factor against breast cancer [36] , while in pediatric leukemia patients after hematopoietic stem cell transplantation, the presence of KIR2DL5A is associated with higher relapse rate [37] . However, few studies had reported the role of KIR2DL5A in monocytes or its role in atherosclerosis, and it might be a promising target to elucidate the molecular mechanism for the progression of carotid atherosclerosis.
SIRT1 was the gene having the highest degree among the 5 crucial genes, and it was downregulated in the events group. SIRT1 is a type of NAD-dependent histone deacetylase [38] and participates in regulating inflammation, apoptosis, and cell senescence [39, 40] . It also plays roles in stress response, aging, and longevity [41, 42] . SIRT1 can also slow the progression of atherosclerosis by lipid modification, oxidative stress reduction, anti-inflammatory actions, foam cells, and autophagy regulation, and downregulation of SIRT1 was observed in a atherosclerotic mouse model [43] , which is consistent with e921692-8 our findings. Recently, Lee et al. discovered that SIRT1 inhibits the adhesion of monocytes to vascular endothelia cells by suppressing MAC-1 expression in monocytes [44] . In addition, Nguyen et al. discovered that a dipeptidyl peptidase 4 inhibitor, evogliptin, can inhibit monocytes adhesion to vascular endothelial cells in an ApoE -/mouse model, and this effect is associated with regulation of NF-kB by SIRT1 [45] . Therefore, SIRT1 might also slow the progression of atherosclerosis by preventing monocytes adhesion, which is the one of the initiation steps in the pathogenesis of atherosclerosis.
The upregulated genes, THRAP3 and RBM43, showed potential diagnostic and prognostic value. THRAP3, thyroid hormone receptor-associated protein 3, is an RNA-processing factors and can also participate in the DNA damage response (DDR) pathway and transcription regulation [46] [47] [48] [49] . Mutations in THRAP3 may cause DNA damage repair defects, and Vohhodina reported that loss of THRAP3 made 293T and U2OS cells more susceptible to DNA-damaging factors [49] . Ino et al. used LNCaP and LNCaP-AI prostate cancer cell lines to demonstrate that THRAP3 phosphorylation can contribute to the acquisition of androgen independence in prostate cancer via transcriptional regulation [48] . Another study, using high-fat-fed mice, found that THRAP3 can act as a transcriptional regulator in diabetes and can control diabetic gene programming [47] . RBM43 is an RNA binding motif protein 43 and its detailed biological function is not known. At present, it is unclear whether THRAP3 and RBM43 participates the pathogenesis of atherosclerosis, although they were found to have potential clinical significance for the occurrence of ischemic events in carotid atherosclerosis patients.
In the present study, for the first time, we constructed a coexpression network, detected genes modules, and identified hub genes and crucial genes in carotid atherosclerosis using PBMC expression data. However, datasets in GEO lack clinical information; therefore, it is difficult to correlate traits with clinical importance with gene modules in WGCNA analysis.
The events group and no-events group had different co-expression patterns, and these differences suggest that monocytes are of vital importance in the pathogenesis and progression of carotid atherosclerosis via mediating inflammation and immune response. Then, we identified hub genes and crucial genes, which might have crucial biological functions in the pathogenesis of carotid atherosclerosis or potential diagnostic and prognostic value for ischemic events.
Conclusions
We detected 8 modules for the events group and 6 modules for the no-events group. The hub genes for each module and crucial genes of the DEG co-expression network were also identified. These genes might serve as potential targets for medical therapies and as biomarkers for diagnosis and prognosis. Further mechanism studies are needed to explore the biological function of these genes in the pathogenesis and progression of carotid atherosclerosis. 
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